MCID: ANL017
MIFTS: 49

Anal Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 12 15 17 74
Epidermoid Anal Carcinoma 12
Carcinoma of Anal Margin 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5525
NCIt 51 C9161

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : 12 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell carcinoma and suppressor of tumorigenicity 3. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human cytomegalovirus infection. The drugs Immunologic Factors and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.0 AKT1 CDKN2A PIK3CA TP53
2 suppressor of tumorigenicity 3 30.4 CDKN2A TP53
3 in situ carcinoma 30.3 CDKN2A TP53
4 cervix carcinoma 30.2 CDKN2A TP53
5 adenocarcinoma 28.8 AKT1 APC CDKN2A MLH1 PIK3CA TP53
6 bladder squamous cell carcinoma 10.3 CDKN2A TP53
7 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
8 spitz nevus 10.3 CDKN2A TP53
9 bladder carcinoma in situ 10.3 CDKN2A TP53
10 vulva squamous cell carcinoma 10.3 CDKN2A TP53
11 scrotal carcinoma 10.3 CDKN2A TP53
12 thyroid lymphoma 10.3 CDKN2A TP53
13 vulvar disease 10.3 CDKN2A TP53
14 nasal cavity adenocarcinoma 10.3 CDKN2A TP53
15 bartholin's gland disease 10.3 CDKN2A TP53
16 megaesophagus 10.3 CDKN2A TP53
17 glycogen-rich clear cell breast carcinoma 10.3 CDKN2A TP53
18 gastric adenosquamous carcinoma 10.3 CDKN2A TP53
19 anogenital venereal wart 10.3 CDKN2A TP53
20 cervix uteri carcinoma in situ 10.3 CDKN2A TP53
21 uterus carcinoma in situ 10.3 CDKN2A TP53
22 oral leukoplakia 10.3 CDKN2A TP53
23 meningeal melanomatosis 10.3 CDKN2A TP53
24 hyperplastic polyposis syndrome 10.3 APC TP53
25 dedifferentiated liposarcoma 10.3 CDKN2A TP53
26 endocervical adenocarcinoma 10.3 CDKN2A TP53
27 mutyh-associated polyposis 10.3 APC TP53
28 penile disease 10.3 CDKN2A TP53
29 cervix small cell carcinoma 10.3 CDKN2A TP53
30 necrotizing sialometaplasia 10.3 CDKN2A TP53
31 verrucous carcinoma 10.3 CDKN2A TP53
32 basaloid squamous cell carcinoma 10.3 CDKN2A TP53
33 tongue disease 10.3 CDKN2A TP53
34 optic nerve neoplasm 10.3 CDKN2A TP53
35 juvenile pilocytic astrocytoma 10.2 CDKN2A TP53
36 tonsil cancer 10.2 CDKN2A TP53
37 pre-malignant neoplasm 10.2 CDKN2A TP53
38 polyposis syndrome, hereditary mixed, 1 10.2 APC MLH1
39 vulva cancer 10.2 CDKN2A TP53
40 anaplastic oligodendroglioma 10.2 CDKN2A MGMT
41 squamous cell papilloma 10.2 CDKN2A TP53
42 adult hepatocellular carcinoma 10.2 PIK3CA TP53
43 malignant spiradenoma 10.2 PIK3CA TP53
44 papilloma 10.2
45 breast squamous cell carcinoma 10.2 PIK3CA TP53
46 laryngeal disease 10.2 CDKN2A TP53
47 breast giant fibroadenoma 10.2 CDKN2A MGMT
48 richter's syndrome 10.2 MLH1 TP53
49 barrett's adenocarcinoma 10.2 CDKN2A TP53
50 oropharynx cancer 10.2 CDKN2A TP53

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to Anal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

27 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.8 PIK3CA
2 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.8 FBXW7
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.8 FBXW7
4 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.8 APC
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.8 FBXW7
6 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.8 FBXW7 PIK3CA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.8 AKT1 PIK3CA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.8 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.8 AKT1 APC FBXW7 PIK3CA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.8 FBXW7
11 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.8 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.8 APC
13 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.8 APC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.8 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.8 AKT1 PIK3CA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.8 FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.8 APC PIK3CA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.8 AKT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.8 FBXW7
20 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.8 AKT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.8 APC
22 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.8 AKT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.8 AKT1
24 Decreased CDKN1A mRNA expression GR00389-S-1 9.13 FBXW7 TP53
25 Decreased CDKN1A mRNA expression GR00389-S-2 9.13 TP53

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.11 AKT1 APC CDKN2A FBXW7 MGMT MLH1
2 homeostasis/metabolism MP:0005376 10.1 AKT1 APC CDKN2A FBXW7 MGMT MLH1
3 cellular MP:0005384 10.09 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
4 cardiovascular system MP:0005385 10.03 AKT1 APC CDKN2A FBXW7 PIK3CA TP53
5 immune system MP:0005387 10.02 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
6 mortality/aging MP:0010768 10.01 AKT1 APC CDKN2A FBXW7 MGMT MLH1
7 embryo MP:0005380 10 AKT1 APC CDKN2A FBXW7 PIK3CA TP53
8 integument MP:0010771 10 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
9 digestive/alimentary MP:0005381 9.93 APC CDKN2A FBXW7 MLH1 TP53
10 neoplasm MP:0002006 9.92 AKT1 APC CDKN2A FBXW7 MGMT MLH1
11 liver/biliary system MP:0005370 9.83 AKT1 APC CDKN2A FBXW7 TP53
12 muscle MP:0005369 9.77 AKT1 APC CDKN2A PIK3CA TP53
13 reproductive system MP:0005389 9.63 AKT1 APC CDKN2A MLH1 PIK3CA TP53
14 no phenotypic analysis MP:0003012 9.56 CDKN2A MGMT PIK3CA TP53
15 respiratory system MP:0005388 9.43 AKT1 CDKN2A FBXW7 MGMT MLH1 TP53
16 vision/eye MP:0005391 9.1 APC CDKN2A FBXW7 MLH1 PIK3CA TP53

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
3
Cisplatin Approved Phase 3,Phase 2 15663-27-1 441203 84093 2767
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
5
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
6 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
8 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antimitotic Agents Phase 3,Phase 2
10 Albumin-Bound Paclitaxel Phase 3,Phase 2
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
12 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
14 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
17
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
18
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
19
Panitumumab Approved, Investigational Phase 2,Phase 1 339177-26-3 50070211
20
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 6857599 5310940 9887054 43805
21
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
22
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
23
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
24
Pembrolizumab Approved Phase 2 1374853-91-4
25 Antineoplastic Agents, Immunological Phase 2,Phase 1
26 Protein Kinase Inhibitors Phase 2
27 ON 01910 Phase 2
28 Immunoglobulins Phase 2,Phase 1
29 Antibodies Phase 2,Phase 1
30 Antibodies, Monoclonal Phase 2,Phase 1
31 Antimanic Agents Phase 2
32 Tranquilizing Agents Phase 2
33 Central Nervous System Depressants Phase 2
34 Anticonvulsants Phase 2
35 Neurotransmitter Agents Phase 2
36 GABA Agents Phase 2
37 Psychotropic Drugs Phase 2
38 taxane Phase 2
39
Fludarabine Approved Phase 1 75607-67-9, 21679-14-1 30751
40
nivolumab Approved Phase 1 946414-94-4
41
Cyclophosphamide Approved, Investigational Phase 1 6055-19-2, 50-18-0 2907
42
Ipilimumab Approved Phase 1 477202-00-9
43
Manganese Approved, Nutraceutical Phase 1 7439-96-5 27854
44 Vaccines Phase 1
45 Antineoplastic Agents, Alkylating Phase 1
46 Antirheumatic Agents Phase 1
47
Dimenhydrinate Approved 523-87-5 441281
48
Hydrogen peroxide Approved, Vet_approved 7722-84-1 784
49
Ethanol Approved 64-17-5 702
50 Pharmaceutical Solutions

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
2 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
3 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
4 Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
5 Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
6 Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
7 Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
8 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
9 Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
10 Vectibix for the Treatment of Anal Cancer Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
11 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed NCT00324415 Phase 2 cisplatin;fluorouracil
12 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
13 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
14 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
15 A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
16 Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
17 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
18 Avelumab With Valproic Acid in Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
19 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
20 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus Active, not recruiting NCT01581840 Phase 1, Phase 2 radiochemotherapy;Panitumumab
21 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
22 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Active, not recruiting NCT00316888 Phase 2 cisplatin;fluorouracil
23 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
24 A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer Active, not recruiting NCT02797964 Phase 1, Phase 2 SRA737
25 A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Withdrawn NCT02857608 Phase 2 Lymphoseek
26 A Phase 1 Study in Participants With Advanced Cancer Completed NCT01115790 Phase 1 Prexasertib
27 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
28 Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer Recruiting NCT03386500 Phase 1 BMX-001
29 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
30 Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02408861 Phase 1
31 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting NCT03894618 Phase 1 SL-279252
32 ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Completed NCT02145416
33 Molecular Biology of Anal Cancer in HIV-Positive Patients Completed NCT00952874
34 Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor? Completed NCT03469596
35 Anal Dysplasia in Patients With Inflammatory Bowel Disease Completed NCT01653054 Not Applicable
36 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
37 Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients Recruiting NCT01877135
38 Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III) Recruiting NCT03241680 Not Applicable
39 Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men Recruiting NCT02816879 Not Applicable
40 Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021 Not Applicable
41 Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma Active, not recruiting NCT01858025 Early Phase 1 5-fluorouracil;Mitomycin-C
42 Seville Cohort of People Living With HIV at Risk for Anal Cancer Enrolling by invitation NCT03713229
43 Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Not yet recruiting NCT03061435 Not Applicable
44 Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays Terminated NCT02407561
45 Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer Withdrawn NCT02162641

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

42
Lymph Node, Testes, T Cells, Colon, Cervix

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 117)
# Title Authors Year
1
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
2
Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. ( 30636052 )
2019
3
The Role of Multiagent Chemoradiation in the Management and Prognosis of Anal Squamous Cell Carcinoma. ( 30644029 )
2019
4
Intensity-modulated radiation therapy of anal squamous cell carcinoma: Relationship between delineation quality and regional recurrence. ( 30773194 )
2019
5
Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. ( 30788159 )
2019
6
Distinguishing Anal Squamous Cell Carcinoma and Rectal Squamous Cell Carcinoma in Secondary Data Sets. ( 29420432 )
2018
7
Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. ( 29337772 )
2018
8
Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated? ( 29514401 )
2018
9
Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. ( 29339717 )
2018
10
Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. ( 29296096 )
2018
11
Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. ( 28975226 )
2018
12
HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma. ( 29466950 )
2018
13
Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. ( 29416628 )
2018
14
Anal squamous cell carcinoma - State of the art management and future perspectives. ( 29494827 )
2018
15
The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. ( 29487716 )
2018
16
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. ( 30042063 )
2018
17
Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. ( 30054279 )
2018
18
Oestrogen receptor can be expressed by normal and dysplastic anal squamous epithelia but only rarely by anal squamous cell carcinoma. ( 30062743 )
2018
19
Anal squamous cell carcinoma: are we improving outcomes? ( 30159994 )
2018
20
Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. ( 30194195 )
2018
21
ASO Author Reflections: The Role of Tumor Size in the Prognosis of Anal Squamous Cell Carcinoma: A Validation on the New American Joint Committee on Cancer Subclassification of Stage IIA and B. ( 30367300 )
2018
22
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. ( 30415990 )
2018
23
Radiation Therapy for Anal Squamous Cell Carcinoma: A Retrospective Multicenter Study. ( 30504412 )
2018
24
Multiple primary malignancies in patients with anal squamous cell carcinoma. ( 30505585 )
2018
25
Demographic disparities in delay of definitive chemoradiation for anal squamous cell carcinoma: a nationwide analysis. ( 30603130 )
2018
26
Prognostic Significance of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Anal Squamous Cell Carcinoma: A Systematic Review and a Meta-Analysis. ( 30627062 )
2018
27
Chemotherapeutic Response and Survival for Patients With an Anal Squamous Cell Carcinoma and Low Hemoglobin Levels. ( 30630304 )
2018
28
Anal Squamous Cell Carcinoma in a Patient with Myasthenia Gravis: Is Immunosuppression the Main Underlying Etiology? ( 29348988 )
2017
29
Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. ( 29137429 )
2017
30
The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. ( 29315288 )
2017
31
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. ( 28334399 )
2017
32
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). ( 28841909 )
2017
33
High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role. ( 28453691 )
2017
34
Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. ( 29299360 )
2017
35
Recurrent anal squamous cell carcinoma in a patient who refuses end colostomy: What to do? ( 29100741 )
2017
36
Coincidence or not? A rare case of rectal leiomyosarcoma amidst incidental findings of anal squamous cell carcinoma: case presentation and literature review. ( 28959428 )
2017
37
Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 28893059 )
2017
38
The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. ( 28258896 )
2017
39
Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. ( 29035618 )
2017
40
Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. ( 28747781 )
2017
41
Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 29122359 )
2017
42
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 25984929 )
2016
43
A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. ( 27125703 )
2016
44
A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. ( 27284490 )
2016
45
Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. ( 26818664 )
2016
46
A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. ( 26961789 )
2016
47
Chemoradiotherapy for anal squamous cell carcinoma. ( 27118047 )
2016
48
Anal squamous cell carcinoma in Crohn's disease. ( 27773118 )
2016
49
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. ( 27052656 )
2016
50
Metastatic rectal adenocarcinoma and anal squamous cell carcinoma masquerading as vulvar lymphangioma circumscriptum. ( 27616148 )
2016

Variations for Anal Squamous Cell Carcinoma

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 AKT1 APC PIK3CA TP53
2
Show member pathways
12.82 AKT1 CDKN2A PIK3CA TP53
3
Show member pathways
12.81 AKT1 CDKN2A MLH1 TP53
4
Show member pathways
12.64 AKT1 CDKN2A PIK3CA TP53
5
Show member pathways
12.63 AKT1 APC CDKN2A MLH1 PIK3CA TP53
6 12.57 AKT1 APC CDKN2A MLH1 PIK3CA TP53
7
Show member pathways
12.52 AKT1 APC PIK3CA TP53
8
Show member pathways
12.51 AKT1 CDKN2A PIK3CA TP53
9
Show member pathways
12.47 AKT1 PIK3CA TP53
10
Show member pathways
12.4 AKT1 APC CDKN2A MLH1 PIK3CA TP53
11
Show member pathways
12.33 AKT1 PIK3CA TP53
12 12.33 APC CDKN2A PIK3CA TP53
13
Show member pathways
12.32 AKT1 PIK3CA TP53
14 12.32 CDKN2A MGMT MLH1 TP53
15 12.31 AKT1 APC TP53
16
Show member pathways
12.3 AKT1 APC PIK3CA TP53
17
Show member pathways
12.28 AKT1 PIK3CA TP53
18 12.24 APC CDKN2A TP53
19
Show member pathways
12.2 AKT1 PIK3CA TP53
20 12.2 AKT1 APC CDKN2A PIK3CA TP53
21 12.16 AKT1 PIK3CA TP53
22 12.16 CDKN2A PIK3CA TP53
23
Show member pathways
12.09 AKT1 PIK3CA TP53
24
Show member pathways
12.03 AKT1 PIK3CA TP53
25 12.01 AKT1 APC MLH1 TP53
26 11.99 AKT1 PIK3CA TP53
27
Show member pathways
11.99 AKT1 PIK3CA TP53
28 11.98 AKT1 CDKN2A PIK3CA TP53
29 11.95 AKT1 PIK3CA TP53
30 11.94 AKT1 APC PIK3CA
31 11.91 APC MLH1 TP53
32
Show member pathways
11.87 AKT1 PIK3CA TP53
33 11.85 AKT1 PIK3CA TP53
34 11.83 AKT1 PIK3CA TP53
35 11.72 AKT1 PIK3CA TP53
36
Show member pathways
11.61 AKT1 CDKN2A TP53
37 11.61 AKT1 APC CDKN2A PIK3CA TP53
38 11.55 AKT1 FBXW7 PIK3CA TP53
39
Show member pathways
11.52 AKT1 PIK3CA TP53
40 11.5 AKT1 PIK3CA TP53
41 11.44 AKT1 MLH1 TP53
42 11.4 AKT1 APC CDKN2A MGMT TP53
43
Show member pathways
11.39 MGMT MLH1
44 11.39 AKT1 PIK3CA
45 11.38 AKT1 APC
46 11.37 AKT1 PIK3CA
47 11.36 AKT1 APC PIK3CA TP53
48
Show member pathways
11.34 MLH1 TP53
49 11.3 APC TP53
50 11.25 AKT1 PIK3CA

GO Terms for Anal Squamous Cell Carcinoma

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.17 AKT1 APC CDKN2A FBXW7 MGMT MLH1

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.72 AKT1 PIK3CA TP53
2 cell cycle arrest GO:0007050 9.58 APC CDKN2A TP53
3 protein destabilization GO:0031648 9.56 CDKN2A FBXW7
4 negative regulation of Notch signaling pathway GO:0045746 9.54 AKT1 FBXW7
5 protein kinase B signaling GO:0043491 9.52 AKT1 PIK3CA
6 cellular response to ionizing radiation GO:0071479 9.51 MGMT TP53
7 phosphatidylinositol 3-kinase signaling GO:0014065 9.49 AKT1 PIK3CA
8 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.48 APC CDKN2A
9 vasculature development GO:0001944 9.46 FBXW7 PIK3CA
10 apoptotic mitochondrial changes GO:0008637 9.43 AKT1 CDKN2A
11 negative regulation of macroautophagy GO:0016242 9.37 AKT1 PIK3CA
12 mammary gland epithelial cell differentiation GO:0060644 9.32 AKT1 MGMT
13 replicative senescence GO:0090399 9.26 CDKN2A TP53
14 positive regulation of apoptotic process GO:0043065 9.26 AKT1 APC CDKN2A TP53
15 anoikis GO:0043276 9.16 AKT1 PIK3CA
16 cellular response to DNA damage stimulus GO:0006974 9.02 AKT1 APC MGMT MLH1 TP53

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.43 APC FBXW7 TP53
2 disordered domain specific binding GO:0097718 9.16 CDKN2A TP53
3 protein phosphatase 2A binding GO:0051721 8.96 AKT1 TP53
4 protein kinase binding GO:0019901 8.92 AKT1 APC CDKN2A TP53

Sources for Anal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....